<p>Antibiotic-associated dysbiosis disrupts the gut’s microbial balance, leading to reduced diversity, overgrowth of antibiotic-resistant strains, and compromised gut homeostasis. This can result in inflammation, increased intestinal permeability, impaired immunity, and heightened susceptibility to infections. In this context, probiotics have been highlighted as a promising remedy in alleviating this antibiotic-induced gut microbiome aberrations with subsequent decrease of the detrimental effects. Bifidobacteria, a prominent bacterial group with promising probiotic attributes, have shown effectiveness in restoring the gut microbiome by strong adherence to the colon’s mucosal lining and enhancing the immune response through increased anti-inflammatory cytokines. They also play a crucial role as key producers of acetic acid, which supports butyric acid-producing bacteria essential for colonocyte health during dysbiosis. The synergistic use of bifidobacteria with other probiotic species or prebiotic substrates has further enhanced their survival, colonization capacity, and overall impact on gut microbial restoration. Advanced metagenomic analyses have begun to reveal strain-specific functions, paving the way for personalized probiotic therapies tailored to an individual’s unique microbiome profile. Despite encouraging progress, critical research gaps persist, particularly regarding strain-specific efficacy, formulation stability, long-term outcomes, underlying mechanisms, systemic interactions, and the distinct and specific role of bifidobacteria. Addressing these gaps through targeted clinical investigations is essential to fully harness their therapeutic potential and develop optimized strategies for restoring the microbial balance in the gut microbiome.</p>